Key Points
- New ENDS Authorization: The FDA granted Marketing Granted Orders (MGOs) to Glas G DEVICE and BLONDE TOBACCO 50 MG/ML Pod on March 12, 2026, bringing the total number of authorized ENDS products in the U.S. to 41.
- Flavor Expectations Unmet: Despite earlier industry speculation that Glas could obtain authorization for non-tobacco flavored pods, the newly authorized product remains tobacco-flavored.
- First Addition Since Juul: The decision marks the first expansion of the FDA’s ENDS authorization list since Juul’s approvals in July 2025.
- Small Company Entry: Glas, a small vape manufacturer unaffiliated with major tobacco groups, joining the authorized list challenges the perception that only large tobacco companies can secure PMTA authorization.
- Policy Signal on Flavor: FDA recently issued draft guidance on flavored ENDS, outlining a regulatory pathway for such products, but the absence of flavored approvals in the Glas decision highlights the agency’s continued caution toward non-tobacco flavors.
2Firsts
Shenzhen, March 13, 2026
The U.S. Food and Drug Administration (FDA) has granted marketing authorization to products from California-based vape manufacturer Glas Inc., expanding its list of authorized electronic nicotine delivery systems (ENDS) — though the decision fell short of industry expectations for a flavored approval.
According to an update postedon the FDA website on March 12, 2026 (U.S. Eastern Time), the agency granted marketing authorization to Glas G DEVICE and BLONDE TOBACCO 50 MG/ML Pod under the Premarket Tobacco Product Application (PMTA) pathway.
With the addition, the number of FDA-authorized ENDS products has increased to 41.
The decision marks the first addition to the FDA’s ENDS marketing granted order (MGO) list since July 2025, when the agency authorized one device and four pods from Juul Labs.
While the approval confirms Glas’s entry into the FDA-authorized market, the pod granted authorization is tobacco-flavored rather than a non-tobacco flavor. Prior to the decision, some industry observers had speculated that Glas could become one of the first companies to obtain authorization for flavored ENDS products beyond tobacco.
Earlier December Document Foreshadowed Authorization but Listed More Products
The authorization follows months of speculation surrounding Glas’s regulatory status.
On December 21, 2025, a screenshot circulated on social media suggesting that the FDA had granted marketing authorization to one Glas device and five pods. At the time, the FDA’s official database had not been updated and no formal announcement had been issued.
Following the circulation of the image, 2Firsts conducted a technical reviewof FDA webpages and identified traces of a related authorization document hosted on the agency’s servers. The materials appeared to reference Glas products but could not be fully accessed.
2Firsts subsequently contacted the FDA regarding the document but received no response.
In its March 12 update, the FDA states that “on 12/20/25, FDA experienced a related web error that did not change this list but was corrected the same day.”
While the agency did not elaborate further, the timing appears consistent with the previously circulating authorization image.
The product list in the March update also differs from the earlier version shared online. The circulating document referenced a “Glas G2 device” and multiple pods, while the current authorization lists Glas G DEVICE and a single tobacco-flavored pod.
Glas Previously Positioned Age-Verification Technology as a Pathway for Flavored Products
Glas had previously expressed confidence that its products could obtain FDA authorization by combining flavored ENDS products with age-verification technology designed to limit youth access.
In an interview with 2Firsts in the third quarter of 2025, the company described its G2 platform as incorporating a technology system intended to address regulatory concerns about youth usage.
According to Glas, the system integrates smartphone-based identity verification, proximity restrictions, and anti-counterfeit protections. The company argued that such technology could allow flavored ENDS products to remain available to adult smokers while preventing underage use.
Glas founder and CEO Sean Greenbaum told 2Firsts that the company had submitted its PMTA application in July 2021 and believed its G2 device could be among the next ENDS products to receive authorization.
Greenbaum said at the time that the company expected marketing authorization “within the next months.”
It remains unclear whether Glas G DEVICE incorporates the same technology.
Small Company Approval Seen as Signal of a Broadening ENDS Authorization Pool
Although the authorization did not include non-tobacco flavored products, Glas’s entry into the FDA’s authorized list is still viewed by some industry observers as a positive signal.
In recent years, many in the industry have believed that the complexity and cost of the PMTA process effectively limited ENDS marketing authorization to large multinational tobacco companies and major industry players.
At the same time, the FDA has also signaled support for smaller companies navigating the PMTA pathway. On February 10, 2026, the agency convened a Roundtable on Premarket Tobacco Product Application (PMTA) Submissions for Electronic Nicotine Delivery Systems (ENDS) Products, inviting industry representatives to discuss the challenges companies face when preparing PMTA submissions. Glas sent a representative to attend the meeting.
According to the FDA’s participation criteria, the roundtable targeted small tobacco product manufacturers—defined as companies with fewer than 350 employees.
Against this backdrop, Glas—a small vape manufacturer based in California and not affiliated with any major international tobacco group—joining the authorized list may signal that the pool of companies capable of obtaining ENDS marketing authorization could gradually broaden.
FDA Signals Openness to Flavored ENDS — But Glas Decision Shows Continued Caution
This week, the U.S. vaping industry received two signals from regulators that pointed in different directions.
Earlier in the week, the U.S. Food and Drug Administration (FDA) released a draft guidance titled “Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications – Considerations Related to Youth Risk.”
The document outlines how the FDA evaluates flavored ENDS products under the Premarket Tobacco Product Application (PMTA) framework. It emphasizes that applicants must demonstrate that the benefits to adult smokers outweigh potential risks to youth.
The guidance also notes that flavors with stronger youth appeal—such as fruit, candy, dessert, or other sweet varieties—may face a higher evidentiary burden during PMTA review because of their potential to increase youth initiation and use.
Although the guidance is nonbinding, many industry observers interpret it as a sign that the FDA is continuing to clarify the regulatory pathway for flavored ENDS applications.
However, in the Glas authorization announced Thursday (U.S. Eastern Time), the FDA approved only a tobacco-flavored pod.
The absence of any newly authorized non-tobacco flavored products suggests that the agency remains cautious about approving flavored ENDS.
Taken together, the policy guidance and the authorization decision suggest that while the FDA may be continuing to move forward with PMTA reviews, it is maintaining a cautious regulatory stance toward flavored products.
Notably, 2Firsts reported earlier in March that vape companies Breeze Smoke and Glas had separately requested White House review meetings under Executive Order 12866 regarding the FDA’s draft flavored ENDS guidance (RIN 0910-ZC78). The meetings were requested with the Office of Information and Regulatory Affairs (OIRA), part of the Executive Office of the President.
The filings reflected growing industry attention to how the FDA will evaluate flavored products under the statutory “appropriate for the protection of public health” (APPH) standard, as companies seek greater predictability and transparency in the PMTA review process.
2Firsts will continue to monitor developments in the U.S. PMTA process.
Cover image: The FDA website shows two Glas products granted Marketing Granted Orders (MGOs) on March 12, 2026 (U.S. Eastern Time) | Source: FDA website
Further reading:
